Conceiving the Future: ReproNovo Raises $65M and Redefines Reproductive Medicine
In one of the most sensitive yet technologically advanced fields of modern healthcare — reproductive medicine — a radical shift is on the horizon. Swiss startup ReproNovo, based in Zug, has announced a $65 million Series B funding round. But it’s not just about the number — it’s about the paradigm shift the company aims to bring to the world.
While most IVF clinics still operate within the paradigm of the previous decade, ReproNovo combines AI, automation, tissue engineering, and molecular diagnostics in a modular platform designed to digitize every step of assisted reproduction. From treatment protocol selection to embryo incubation and viability assessment — everything is managed by machine intelligence, replacing human involvement wherever algorithms allow.
The project has attracted investors such as Swisscanto, MTIP, and Investiere. Symbolically, nearly a third of the funding came from female investors, including entrepreneurs in the FemTech space. This is not just a venture — it’s a position and a social declaration. Reproductive medicine is not only about technology; it’s also about ethics, trust, and the future of the family as an institution.
The startup’s CEO, Mario Prestini, states: the goal is to “make IVF not an exception, but the norm — like a visit to the dentist or general practitioner.” With this philosophy, ReproNovo opens the door to a new generation of parents who can rely not on miracles but on clinically validated algorithms.
The first test deployments are expected in Swiss and German clinics this autumn. Next steps include FDA certification, expansion into the U.S. and Asian markets, and perhaps a new chapter in human history — one where the future begins not only with love but also with code.
www.repronovo.com
